Xtant Medical Holdings, Inc. XTNT
0.38
0.00
0.00%
as of 25 Sep
- Market cap
- $52.9M
- P/E
- 0.0×
Follow XTNT
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 27.45 | 19.12 | 31.86 |
+8 more quarters Free account |
P/S ratio |
0.54 | 0.64 | 0.81 | 0.68 | |
P/FCF ratio |
0.00 | 9.81 | 10.47 | 16.56 | |
P/Operating CF |
(8.06) | (37.10) | 20.23 | 19.69 | |
P/B ratio |
1.47 | 1.61 | 2.14 | 1.80 | |
Price to Tangible BV |
1.75 | 1.86 | 2.44 | 2.52 | |
EV/Sales |
0.65 | 0.64 | 0.87 | 0.82 | |
EV/EBITDA |
0.00 | 9.84 | 9.35 | 9.99 | |
EV/Operating CF |
125.76 | 8.58 | 9.32 | 13.91 | |
EV/FCF |
(156.17) | 9.82 | 11.24 | 19.86 | |
Quick Ratio |
0.99 | 1.56 | 1.19 | 1.02 | |
Current Ratio |
2.16 | 3.34 | 2.65 | 2.21 | |
Net Debt/EBITDA |
(1.47) | (0.04) | 9.22 | 4.89 | |
Debt/Assets |
28.86% | 15.72% | 26.97% | 27.03% | |
Debt/Equity |
0.57 | 0.25 | 0.50 | 0.57 | |
Asset Turnover |
1.20 | 1.40 | 1.42 | 1.30 | |
Operating CF/Net income |
0.78 | 0.68 | 94.39 | 3.53 | |
Capex/Depreciation |
(0.38) | (0.28) | (0.20) | (0.28) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
3.02% | 2.08% | 1.42% | 1.91% | |
Selling, General and Administrative Expense of Revenue |
72.96% | 69.23% | 56.37% | 56.58% | |
Intangible Assets out of Total Assets |
0.08 | 0.08 | 0.07 | 0.14 | |
Share Based Compensation of Revenue |
3.80% | 3.57% | 2.25% | 1.93% | |
Graham Net Nets |
0.43 | 0.42 | 0.32 | 0.25 | |
Graham Number |
0.00 | 0.40 | 0.58 | 0.41 | |
Earnings Yield |
(18.95%) | 3.64% | 5.23% | 3.14% | |
Free Cash Flow Yield |
(0.78%) | 10.20% | 9.55% | 6.04% | |
Revenue per Share |
0.16 | 0.15 | 0.23 | 0.24 | |
Operating CF per Share |
(0.05) | (0.02) | 0.04 | 0.03 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.05) | (0.02) | 0.04 | 0.03 | |
Cash per Share |
0.07 | 0.09 | 0.12 | 0.08 | |
Shareholders Equity per Share |
0.29 | 0.35 | 0.37 | 0.36 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.29 | 0.35 | 0.37 | 0.36 | |
Free Cash Flow |
(7.50) | (2.26) | 5.01 | 4.29 | |
Working Capital |
34.81 | 43.85 | 48.76 | 42.83 | |
Capital Expenditures |
(0.19) | (0.15) | (0.37) | (0.32) | |
Net Current Asset Value |
25.13 | 33.22 | 35.05 | 22.39 | |
EV/EBIT |
0.00 | 23.81 | 16.05 | 17.16 | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.01 | |
Net Profit Margin |
(40.87%) | (14.79%) | 0.18% | 3.93% | |
Price to Operating Income |
0.00 | 23.78 | 14.94 | 14.31 | |
| Other line items | |||||
Average Receivables |
23.18 | 20.33 | 19.23 | 23.03 | |
Average Payables |
6.69 | 6.30 | 5.88 | 7.58 | |
Average Inventory |
36.71 | 35.35 | 34.45 | 41.30 | |
Average Assets |
91.57 | 86.92 | 93.99 | 102.60 | |
Average Common Equity |
44.26 | 46.24 | 46.96 | 48.05 |
Columns are period end dates